Company: LIMN
Filing Date: 2025-06-02
Form Type: 8-K/A
Source: 0001104659-25-055078
Chunk: 31

Company: Liminatus Pharma, Inc.
Filing Date: 2025-06-02
Form: 8-K/A
Chunk 31
---
 Registrant with the SEC on April 30, 2025).                                                                                                                                                                                                        |
| 99.5**  |     | Unaudited financial statements of Liminatus Pharma, LLC for the three months ended March 31,                                                                                                                                                                                                                                                 
 2025 and 2024.                                                                                                                                                                                                                                                                                                                               |
| 99.6**  |     | Management’s Discussion and Analysis of Financial Condition and Results of Operations                                                                                                                                                                                                                                                        
 for Liminatus Pharma, LLC for the three months ended March 31, 2025.                                                                                                                                                                                                                                                                         |
| 99.7**  |     | Unaudited financial statements of Iris Acquisition Corp for the three months ended March 31,                                                                                                                                                                                                                                                 
 2025 and 2024.                                                                                                                                                                                                                                                                                                                               |
| 99.8**  |     | Management’s Discussion and Analysis of Financial Condition and Results of Operations for Iris                                                                                                                                                                                                                                               
 Acquisition Corp for the three months ended March 31, 2025.                                                                                                                                                                                                                                                                                  |
| 104**   |     | Cover Page Interactive Data File (formatted as Inline XBRL)                                                                                                                                                                                                                                                                                  |

| ** | Filed herewith. |

<div align='center'>20

SIGNATURES</div>

Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| Dated: May 30, 2025 |                        |                         |
|:--------------------|:-----------------------|:------------------------|
|                     | LIMINATUS PHARMA, INC. |                         |
|                     | By:                    | /s/ Chris Kim           |
|                     | Name:                  | Chris Kim               |
|                     | Title:                 | Chief Executive Officer |

<div align='center'>21</div>